Cargando…

Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

We investigated distant recurrence and S-phase fraction (SPF), estimated by flow cytometry with and without selection of the epithelial cell population, in 201 stage II breast carcinomas. The tumour tissue was disintegrated mechanically by scissors and one part of the cell suspension was treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wingren, S., Stål, O., Nordenskjöld, B.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1994
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968862/ https://www.ncbi.nlm.nih.gov/pubmed/7510119

Ejemplares similares

p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.
por: Stenmark-Askmalm, M., et al.
Publicado: (1995)

Flow Cytometric Bivariate Analysis of DNA and Cytokeratin in Colorectal Cancer
por: Post, Carolin, et al.
Publicado: (2002)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.
por: Stål, O., et al.
Publicado: (1994)

Evaluation of Prognostic Factors Following Flow-Cytometric DNA Analysis after Cytokeratin Labelling: I. Breast Cancer
por: Wimberger, Pauline, et al.
Publicado: (2002)

Flow Cytometric DNA Analysis Using Cytokeratin Labeling for Identification of Tumor Cells in Carcinomas of the Breast and the Female Genital Tract
por: Kimmig, Rainer, et al.
Publicado: (2001)

Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients.
por: Stål, O., et al.
Publicado: (1992)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
por: Wegman, Pia, et al.
Publicado: (2007)

Evaluation of Prognostic Factors Following Flow-Cytometric DNA Analysis after Cytokeratin Labelling: II. Cervical and Endometrial Cancer
por: Wimberger, Pauline, et al.
Publicado: (2002)

Flow cytometric analysis of tumour infiltrating lymphocytes in breast cancer.
por: Whitford, P., et al.
Publicado: (1990)

Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Biological Characterisation of Superficial Bladder Cancer by Bivariate Cytokeratin 7/DNA Analysis, Flow Cytometric Assessment of MIB-1, and an Immunohistochemical Study
por: Leonardi, Elena, et al.
Publicado: (2000)

Automatic, fast, hierarchical, and non-overlapping gating of flow cytometric data with flowEMMi v2
por: Bruckmann, Carmen, et al.
Publicado: (2022)

Flow cytometric analysis of cell surface carbohydrates in metastatic human breast cancer.
por: Alam, S. M., et al.
Publicado: (1990)

Histopathologic and Flow-Cytometric Analysis of Neoplastic and Benign “background” Tissue in Breast Carcinoma Resections
por: Visscher, Daniel W., et al.
Publicado: (1998)

Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates.
por: Brotherick, I., et al.
Publicado: (1995)

Flow cytometric S-phase fraction in soft-tissue sarcoma: prognostic importance analysed in 160 patients.
por: Gustafson, P., et al.
Publicado: (1997)

Wide-field imaging and flow cytometric analysis of cancer cells in blood by fluorescent nanodiamond labeling and time gating
por: Hui, Yuen Yung, et al.
Publicado: (2014)

Flow cytometric characterization of acute leukemia reveals a distinctive “blast gate” of murine T-lymphoblastic leukemia/lymphoma
por: Pan, Zengkai, et al.
Publicado: (2017)

An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas
por: Wang, Yu, et al.
Publicado: (2013)

A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum
por: Smith, Edward R., et al.
Publicado: (2017)

Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya
por: Ermiah, Eramah, et al.
Publicado: (2012)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer
por: Stal, O, et al.
Publicado: (2000)

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
por: Karlsson, Elin, et al.
Publicado: (2018)

Flow Cytometric Detection of Proliferative Cells in Leukemias
por: Wakita, Atsushi, et al.
Publicado: (1994)

Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.
por: Camplejohn, R. S., et al.
Publicado: (1993)

Breast Implanted-Associated Anaplastic Large Cell Lymphoma: A Case of Advanced Disease with Flow Cytometric Findings
por: Demko, Nadine, et al.
Publicado: (2022)

Flow cytometric techniques for isolating and analysing leucocytes
por: Rossi, Adriano G, et al.
Publicado: (2015)

Flow Cytometric Analysis of T Cells in Hemophagocytic Lymphohistiocytosis
por: Park, Min-Seung, et al.
Publicado: (2019)

Flow Cytometric Analysis of Efflux by Dye Accumulation
por: Whittle, Emily E., et al.
Publicado: (2019)

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer
por: Gusterson, Barry A, et al.
Publicado: (2005)

Cytokeratin and mammaglobin as tumor markers in patients with high risk breast cancer
por: Ferrucci, PF, et al.
Publicado: (2000)

EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer
por: Serrano, Maria J., et al.
Publicado: (2014)

Cytokeratin 5 alters β-catenin dynamics in breast cancer cells
por: McGinn, Olivia, et al.
Publicado: (2020)

Akt kinases in breast cancer and the results of adjuvant therapy
por: Stål, Olle, et al.
Publicado: (2003)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer
por: Hilborn, Erik, et al.
Publicado: (2016)

Flow cytometric analysis of hematologic neoplasms : a color atlas & text /
por: Sun, Tsieh
Publicado: (2002)

The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_v1aodcrm4890d67feq0hic5jkn